Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Faron Pharmaceuticals, Q2'24

By Inderes8/28/2024, 12:00 PM
Faron Pharmaceuticals

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Uriah
00:01 - 01:17

Welcome, everybody, to the H1 results webcast of Faron Pharmaceuticals. My name is Uriah, and I am the CEO of the company. I hope you've all had a relaxing summer charging your batteries because we have an action-packed second half coming up. But before we delve into that, let's review what the first half looked like. A standard disclaimer because we will be making some forward-looking statements. But then, what brings us all together here? Relapsed/refractory MDS, a dreadful condition. Very poor survival, basically. No effective treatment options, nothing. On the other hand, what can we possibly bring to the table? We can extend survival. We have an excellent response rate; we can possibly truly change the treatment paradigm in this condition. But now, to the actual H1 results, I'm going to hand it over to our Chief Financial Officer, David.

David Hyman
01:18 - 03:15

Hello, my name is David Hyman. I'm the Chief Financial Officer of Faron, and it's my pleasure to give you the highlights of the H1 financial results. Results: As you might have heard, we completed a substantial fundraising effort in the first half, which led to us having a plus 30 million cash balance at the end of June. We have sufficient funds to support our operations through the first quarter of 2025. Our operating loss was slightly lower than the last year's period. It fluctuates from year to year, so it's nothing exceptional in this respect. And as mentioned, we raised 35.5 million through a fairly extensive transaction that extended across both the UK and Finland markets, and also included retail investors from both countries. As a result, we had roughly 105 million shares outstanding at the end of the first half. And the board still has authorization to issue 19.1 million shares, which is available until the end of the first half next year. After this transaction, our trading volume has gone up substantially. We have the largest share trading volume among the first node companies on the Helsinki First Node. And our market cap is among the largest in the Helsinki First Node. So, we have actually quite well succeeded in broadening our shareholder base and increasing the liquidity of the share. So that was, in a nutshell. Over to you.

Uriah
03:15 - 06:30

Thank you. As you mentioned, we have truly changed the stock. I would say H1 has been truly transformational. That word, 'transformational', I see often used, but I seldom see it truly reflected in this respect that the changes we've done. But let's go over the sequence of events we've seen during H1. We started off well and going into phase two in relapsed refractory MDS with Bexmarilimab. After that, though, many of you are aware of the capital market situation that has been going on for some while now in the biotech sector, we too were not immune to it and we hit the minimum cash level set by IPF partners. We quickly took corrective measures and conducted two consecutive small bridging rounds after that. And then we did significant cuts in headcount and our operative costs, which you've just seen in your report. Then we had a CEO and CFO change, which is always a big thing for a company like us. We then continued to show the excellent results in phase two that we had seen already in phase one, which then led us to conduct a substantial public and institutional offering both in Helsinki and London to become a healthy, strong company funded to complete phase two. So that's the sequence and events. And I would say we accomplished this very well because, as you mentioned, we ended up raising 35.5 million, which is a record for the company and is a landmark raise in the Nordics for biotech. I would say during this year we've continued to produce outstanding results in our clinical trial. We've also taken this data to the FDA and received, I would say, exceptional feedback. We had a Fast Track Designation. Just granted, we now have an Accelerated Approval program basically stamped by the FDA. I dare to say we are the most exciting and advanced asset in development for the treatment of relapsed refractory MDS, and we are now the industry-leading macrophage reprogramming agent. If you look at our results, others have not achieved such results as we have. So at the end of the day, we have transformed into a financially very healthy, cost-effective company. That's here to deliver on our strategic objectives to complete phase two and partner as already communicated to the market. Now it gives me great pleasure to introduce a new face to the company. I welcome to the stage our new chief medical officer, Doctor Patrick Bono. Welcome, Patrick. Thank you. Nice to have you on board. Thank you.

Patrick Bono
06:30 - 07:58

Great to be here on stage. And good afternoon, everyone. So, I'm more than delighted to be welcomed by you. Today on stage and happy to tell you about some recent advances. And, before I go into them. I'd like to introduce myself a bit. So my name is Patrick Bono. I'm a medical oncologist by my basic training and also associate professor of cancer biology at the University of Helsinki. Before joining the service, I was the chief medical officer at the largest private healthcare provider company in Finland, and before that I was in various leadership positions at the Helsinki University Hospital, including director of the Comprehensive Cancer Center for six and a half years. I'm fairly familiar with Mesmer Lab, our leading asset, since I have also been the principal investigator in the global phase. First in man, phase one trial with Bexmarilimab in solid tumors. But that's about my background. I'm more than excited to tell you about the recent progress we've had, and also to open up about what to expect in the fall and winter. Um, so what we have in the.

Uriah
07:58 - 08:00

The audience is expecting. Great.

Patrick Bono
08:01 - 13:36

Let's start with this fascinating news from the FDA. First of all, already in July, we announced the positive feedback from the FDA regarding the clinical development plan registration for Bexmarilimab, or Bex as we call it, for the treatment of high-risk myelodysplastic syndromes (MDS). In a nutshell, this means that only one randomized Phase 3 trial is required from us to gain approval. This week, on Monday, we had a recent press release about the FDA's latest decision, granting Fast Track Designation for the treatment of relapsed or refractory myelodysplastic syndromes (r/r MDS) in combination with acetaldehyde. And, as you can see from the bullet points, this is what it signifies. In practice, it means more frequent meetings with the FDA to discuss the development path and plan, to ensure correct collection of data needed for the full approval. And also, it means eligibility for accelerated approval. And prior to the review, if relevant criteria are met. And what are these relevant criteria? There is an unmet medical need for the disease. It is a serious and important disease that lacks suitable treatments. And we need to remember that when we're talking about relapsed MDS. So the current overall survival with the current agents. So it's around six to seven months in median. And it means that it's a number that we see as an overall figure in metastatic pancreatic cancer. So it's a deadly disease. But then let's move forward, after this exciting FDA news, how does H2 look? And then, what can you expect to see from us next? First of all, we will have an R&D day and provide further market guidance on vaccine maps and the cancer development plan, as well as an update on the ongoing Phase 2 survival data. In October 2024. Unfortunately, I cannot at this stage tell you the exact date. But anyway, in October. In October, so you won't need to wait a long time. When we open up our R&D pipeline. Then, about the next Mab—MDS recruitment status. So, it's running, it's enrolling, it's enrolling. Recruitment is projected to be completed by the end of the year or by the end of Q4 2024, followed by major future releases of the results. So, they will be at the medical congresses, as is typical in the industry. The current plan is that the next data release, from Basemap, will involve new patients. So that will be at the ASH meeting, the American Society of Hematology meeting taking place in December, and then thereafter. The next one will be next June at ASCO, the American Society of Clinical Oncology Annual Meeting, or the European Hematology Association meeting. So, those are the time points where you can expect to get more data, for example, from the response rates and duration of responses and so on. So we transition to what is considered a standard rhythm of reporting scientific results from enrolling in clinical trials. I'm really happy to announce that in solid tumors, we are also making progress with the pipeline, specifically, our first PD-1 inhibitor combination trial. So, the preparations have been initiated, and this will be the first trial to examine the safety and, of course, also the preliminary efficacy of Bexmarilimab's PD1 inhibitor combo or Bexmarilimab's checkpoint inhibitor combination. And the first trial site. It will be at the Royal Marsden Hospital in London, UK, but there will be more about the development plan in solid tumors in October during the R&D day.

Uriah
13:38 - 13:51

Thank you, Patrick. Great segue to open the floor to questions. It's great to see so many of you here today. Please, the stage is yours, and we're happy to answer almost anything.

Unknown 1
13:56 - 14:14

Thanks very much, Juho. Um, first question, can you say anything more about your discussions with partners? So have you initiated discussions with relevant companies, and if so, can you provide an indication of how many, and what is your target to complete those discussions?

Uriah
14:15 - 14:44

Thank you. I know that many await answers to these questions. One must understand that these discussions, which are ongoing or under strict confidentiality, cannot be speculated upon. We cannot provide guidance and timelines for that. That's just industry standard. So, for the audience, I must emphasize that you have to keep your head cool and hold the line.

Unknown 1
14:48 - 15:00

Financial question: Will the cash runway extend into Q1 2025, covering the completion of the Phase 2 trial as well as the initiation of Phase 3?

David Hyman
15:01 - 15:03

This is most probably for me. Uh, over.

Uriah
15:04 - 15:04

Error: No content provided for correction.

David Hyman
15:04 - 15:36

We will conclude the recruitment by the end of 2024. But the current cash runway, based on the covenants, would be in breach by the end of Q1, and we would not be able to have the full readout of the phase two trial. So it will be close, but not close enough.

Uriah
15:37 - 15:59

I'll just elaborate on that. When the readout comes, we're going to start looking at the covenant level. They're pretty right there. The readout will focus on the response rate. But never in our plans did we intend to enter phase three with the current amount. So again, as previously communicated, we are looking to partner for phase three.

Unknown 1
16:04 - 16:17

Okay. Regarding the potential for an Accelerated Approval in the relapsed setting. What magnitude of response rate do you believe would be required?

Uriah
16:19 - 16:55

You want to take it or should I? So actually discussing with leading colleagues in the world on this and also with the FDA. So they will be concentrating on CR and PR, and that is basically currently 0 to 5% with the existing treatments. And we're at 15 to 20. So that's the magnitude of CR and PR we would like to see for approval. Our FDA would like to see approval.

Unknown 1
16:58 - 17:11

Thank you. So, are you including frontline high-risk MDS patients? Are you no longer recruiting?

Unknown 2
17:13 - 17:13

Um.

Unknown 1
17:14 - 17:29

Refractory MDS patients, without providing any internal guidance. I'm here to assist with editing the transcripts for financial webcasts, not to provide answers to new queries. Um, is there any upside in targeting both populations?

Patrick Bono
17:30 - 17:36

I can tell you about the recruitment status. We are currently enrolling both frontline and relapsed patients.

Uriah
17:37 - 18:46

And regarding the markets, as mentioned, relapsed/refractory is a basically untapped market with still a significant number of patients. We're talking tens of thousands. Uh, then in the frontline setting, a significantly bigger market. Regarding the market dynamics, our main competitor, with Venetoclax, has a combination trial running in Phase 3 for the frontline setting. If it's positive, it is likely to become the new standard of care. How do we fit into that picture? First of all, our safety profile is significantly better. We believe our survival rates will be improved, as it's well-known. If you refer back, Venetoclax typically performs even worse than refractory on AZA alone. Moreover, we've shown in the relapsed refractory population that we can also be effective after a combination of AZA and Venetoclax. So in the front line, there's plenty of space to play. And if the AZA-Venetoclax trial is negative, then it opens up a niche just for us. The frontline is a major market.

Unknown 1
18:49 - 18:59

What is the optimal plan for progressing to the pivotal trial? Is it licensing after the Mab data or another capital raise to finance that trial?

Uriah
19:00 - 19:33

That's a very good question. And that's what we aim to optimize at the moment. As the Phase 2 readout approaches completion, that's when you'll likely get the best deal. But then we're going to be close to running on fumes. So I'm going to say that that would take it all the way and maximize your deal value. That would require a capital raise. However, partnering is in motion and we're likely to secure a partner before then.

Unknown 1
19:36 - 19:44

There was a question about the Fast Track Designation that was announced this week. How will that benefit the company going forward?

Patrick Bono
19:47 - 20:08

Of course, it's a clear signal from the regulatory authorities about the potential of the asset. Now it is not just seen as an exceptional agent by us, but also the regulators think it's of special interest. That's why Fast Track Designation was granted for Bexmarilimab in the treatment of MDS.

Uriah
20:09 - 20:56

And just to add to that, as I've discussed this with some investors, we've been asked about external validation of our drug. This Fast Track Designation is the best external validation you can receive from a regulatory authority like the FDA. So, for example, we often get asked why there aren't any major venture capitalists (VCs) or pharmaceutical companies involved yet. Well, I could say pharmaceutical companies are showing interest. VCs are known for the magnitude of tickets for funding Phase 3. But we're likely to partner and not raise funds to go into Phase 3 alone. So this is the ticket you get from the U.S. Food and Drug Administration (FDA). They have now validated its technology. They believe in the technology. They want to go forward with us in partnership to develop this.

Unknown 1
21:00 - 21:02

Thanks very much. That's all the questions here.

Uriah
21:03 - 21:10

Thank you, everybody. Have a safe trip home. Stay tuned for more exciting news.

Patrick Bono
21:11 - 21:11

Thank you.

David Hyman
21:13 - 21:13

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…